Study Summary
This trial is testing the side effects and best dose of minnelide given with osimertinib to treat non-small cell lung cancer that has spread and has a mutation in the EGFR gene.
- Non-Small Cell Lung Carcinoma
- Non-Small Cell Lung Cancer
- Stage III Lung Cancer
- Stage IIIA Lung Cancer
- Stage IIIB Lung Cancer
- Stage IV Lung Cancer
- Stage IVA Lung Cancer
- Stage IVB Lung Cancer
Treatment Effectiveness
Effectiveness Progress
Study Objectives
2 Primary · 7 Secondary · Reporting Duration: Up to 2 years
Trial Safety
Safety Progress
Side Effects for
Trial Design
1 Treatment Group
Treatment (minnelide, osimertinib)
1 of 1
Experimental Treatment
30 Total Participants · 1 Treatment Group
Primary Treatment: Osimertinib · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Is enrollment available for this research trial at present?
"Yes, data hosted on clinicaltrials.gov affirms that this clinical research is actively welcoming participants. The trial was first made available for review on March 7th 2022 and has been recently refreshed as of August 2nd 2022. 30 individuals will be accepted at the single recruitment site." - Anonymous Online Contributor
Is this an innovative research endeavor?
"Currently, there are 101 active studies for Osimertinib that span 51 countries and 1059 cities. This medication was initially trialled in 2013, with AstraZeneca overseeing a Phase 1 & 2 trial involving 603 patients. Since then, 72 further investigations have been launched into this drug's potential efficacy." - Anonymous Online Contributor
What research has been conducted to explore the efficacy of Osimertinib?
"Presently, there are 101 studies for Osimertinib with 17 in the latter stage of testing. These trials can be found predominantly in Uniondale, NY as well as across 4702 other sites internationally." - Anonymous Online Contributor
To what extent can Osimertinib cause harm to individuals?
"The limited clinical data available surrounding osimertinib's safety and efficacy gives it a score of 1 on our scale." - Anonymous Online Contributor
How many participants are joining this research project?
"Affirmative. According to clinicaltrials.gov, this research trial is actively recruiting participants and has been since March 7th 2022. A total of 30 test subjects need to be sourced from a single medical facility before the last update on August 2nd 2022." - Anonymous Online Contributor